X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6399) 6399
Book Review (1063) 1063
Publication (414) 414
Book / eBook (24) 24
Book Chapter (10) 10
Web Resource (6) 6
Conference Proceeding (5) 5
Dissertation (4) 4
Magazine Article (4) 4
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5979) 5979
humans (5611) 5611
female (4237) 4237
oncology (3037) 3037
middle aged (2828) 2828
peritoneal neoplasms - drug therapy (2778) 2778
male (2468) 2468
aged (2277) 2277
adult (2087) 2087
cancer (1962) 1962
peritoneal neoplasms - secondary (1954) 1954
chemotherapy (1815) 1815
antineoplastic combined chemotherapy protocols - therapeutic use (1491) 1491
surgery (1470) 1470
animals (1330) 1330
ovarian neoplasms - drug therapy (1283) 1283
combined modality therapy (1199) 1199
peritoneal neoplasms - surgery (1114) 1114
treatment outcome (1094) 1094
ovarian cancer (1070) 1070
peritoneal neoplasms - pathology (953) 953
prognosis (912) 912
mice (898) 898
peritoneal carcinomatosis (824) 824
ovarian neoplasms - pathology (819) 819
cytoreductive surgery (812) 812
peritoneal neoplasms - therapy (808) 808
stomach neoplasms - pathology (767) 767
survival rate (761) 761
medicine & public health (725) 725
antineoplastic agents - therapeutic use (709) 709
neoplasm staging (707) 707
retrospective studies (700) 700
antineoplastic agents - administration & dosage (694) 694
metastasis (677) 677
carcinoma (671) 671
cisplatin - administration & dosage (662) 662
obstetrics & gynecology (659) 659
hyperthermia, induced (643) 643
cisplatin (639) 639
stomach neoplasms - drug therapy (639) 639
care and treatment (638) 638
aged, 80 and over (635) 635
infusions, parenteral (618) 618
survival (575) 575
peritoneal neoplasms - mortality (569) 569
analysis (564) 564
chemotherapy, adjuvant (520) 520
intraperitoneal chemotherapy (500) 500
tumors (500) 500
follow-up studies (489) 489
paclitaxel (487) 487
research (487) 487
hematology, oncology and palliative medicine (482) 482
cell line, tumor (472) 472
disease-free survival (469) 469
health aspects (465) 465
carcinoma - drug therapy (443) 443
injections, intraperitoneal (435) 435
survival analysis (428) 428
paclitaxel - administration & dosage (425) 425
antineoplastic combined chemotherapy protocols - administration & dosage (423) 423
surgical oncology (401) 401
therapy (400) 400
carcinomatosis (396) 396
liver neoplasms - secondary (396) 396
colorectal cancer (390) 390
colorectal-cancer (390) 390
abridged index medicus (388) 388
colorectal neoplasms - pathology (382) 382
drug administration schedule (376) 376
hyperthermic intraperitoneal chemotherapy (374) 374
adenocarcinoma - drug therapy (373) 373
pharmacology & pharmacy (367) 367
trial (357) 357
ovarian neoplasms - surgery (352) 352
neoplasm recurrence, local - drug therapy (351) 351
gastric cancer (347) 347
management (346) 346
stomach neoplasms - surgery (345) 345
antineoplastic combined chemotherapy protocols - adverse effects (344) 344
gynecologic-oncology-group (340) 340
fluorouracil - administration & dosage (335) 335
peritoneal neoplasms - metabolism (318) 318
mice, inbred balb c (315) 315
ovarian-cancer (313) 313
prospective studies (311) 311
lymphatic metastasis (307) 307
stomach cancer (306) 306
mice, nude (303) 303
bevacizumab (296) 296
gastroenterology & hepatology (292) 292
time factors (290) 290
peritoneum (286) 286
fallopian tube neoplasms - drug therapy (284) 284
adenocarcinoma - secondary (282) 282
hipec (278) 278
tomography, x-ray computed (278) 278
expression (275) 275
mortality (274) 274
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (11) 11
Online Resources - Online (6) 6
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Dentistry (Harry R Abbott) - Withdrawn (1) 1
Humber River Regional Hospital - Church Stacks (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Scarborough Hospital - General (1) 1
St. Michael's Hospital - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5630) 5630
Japanese (463) 463
French (108) 108
German (81) 81
Italian (39) 39
Chinese (31) 31
Spanish (26) 26
Russian (24) 24
Hungarian (9) 9
Polish (9) 9
Romanian (7) 7
Danish (6) 6
Dutch (6) 6
Finnish (3) 3
Bulgarian (2) 2
Swedish (2) 2
Arabic (1) 1
Hebrew (1) 1
Korean (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | BRCA MUTATION | POLY(ADP-RIBOSE) POLYMERASE | RANDOMIZED PHASE-2 | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | PROSTATE-CANCER | INHIBITORS | DNA-REPAIR | NEGATIVE BREAST-CANCER | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer | Index Medicus
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2654 - 2663
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line... 
POLY(ADP-RIBOSE) POLYMERASE | CLEAR-CELL | ONCOLOGY | RESISTANCE | IMPROVED SURVIVAL | HOMOLOGOUS RECOMBINATION | CARCINOMA | CARRIERS | TUMORS | CHEMOTHERAPY | FEATURES | Medical History Taking | Recurrence | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Case-Control Studies | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Carcinoma, Endometrioid - genetics | Kaplan-Meier Estimate | Mutation Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Australia - epidemiology | Ovarian Neoplasms - epidemiology | Disease-Free Survival | Point Mutation | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Aged | Platinum Compounds - administration & dosage | Neoplasm Staging | Adenocarcinoma, Clear Cell - genetics | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Index Medicus | Original Reports | Gynecologic Cancer | Gync21 | Gync15
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 12/2015, Volume 33, Issue 34, pp. 4015 - 4022
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2010, Volume 28, Issue 15, pp. 2512 - 2519
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 2014, Volume 20, Issue 3, pp. 764 - 775
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 13, pp. 1442 - 1450
Summary Background Poor prognosis germ-cell tumours are only cured in about half of patients. We aimed to assess whether treatment intensification based on an... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | 1ST CYCLE | ETOPOSIDE | THERAPY | SOUTHWEST-ONCOLOGY-GROUP | CISPLATIN | ONCOLOGY | DENSE CHEMOTHERAPY | HIGH-DOSE CHEMOTHERAPY | COMPLETE-RESPONSE | CANCER | Testicular Neoplasms - mortality | Prognosis | Follow-Up Studies | Peritoneal Neoplasms - blood | Humans | Middle Aged | Male | Mediastinal Neoplasms - mortality | Neoplasms, Germ Cell and Embryonal - blood | Testicular Neoplasms - pathology | Cisplatin - administration & dosage | Young Adult | Mediastinal Neoplasms - drug therapy | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Peritoneal Neoplasms - drug therapy | Chorionic Gonadotropin - blood | Adult | Female | Neoplasms, Germ Cell and Embryonal - drug therapy | Paclitaxel - administration & dosage | Precision Medicine | alpha-Fetoproteins - metabolism | Peritoneal Neoplasms - pathology | Mediastinal Neoplasms - blood | Neoplasms, Germ Cell and Embryonal - mortality | Etoposide - administration & dosage | Survival Rate | Bleomycin - administration & dosage | Peritoneal Neoplasms - mortality | Recombinant Proteins - administration & dosage | Biomarkers, Tumor - blood | Ifosfamide - administration & dosage | International Agencies | Testicular Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mediastinal Neoplasms - pathology | Adolescent | Aged | Neoplasm Staging | Testicular Neoplasms - blood | Neoplasms, Germ Cell and Embryonal - pathology | Granulocyte Colony-Stimulating Factor - administration & dosage | Chemotherapy | Tumors | Cancer | Analysis | Index Medicus
Journal Article
British Journal of Cancer, ISSN 0007-0920, 03/2016, Volume 114, Issue 7, pp. 737 - 743
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 20, pp. 2449 - 2456
Journal Article
Annals of oncology, ISSN 0923-7534, 2016, Volume 27, Issue 8, pp. 1386 - 1422
Journal Article